📣 VC round data is live. Check it out!

SenzaGen Valuation Multiples

Discover revenue and EBITDA valuation multiples for SenzaGen and similar public comparables like CurveBeam AI, EBM Technologies, Diagnos, Biosynex and more.

SenzaGen Overview

About SenzaGen

SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.


Founded

2010

HQ

Sweden

Employees

34

Financials (FY)

Revenue: $6M
EBITDA: ($901K)

EV

$18M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

SenzaGen Financials

SenzaGen reported last fiscal year revenue of $6M and negative EBITDA of ($901K).

In the same fiscal year, SenzaGen generated $4M in gross profit, ($901K) in EBITDA losses, and had net loss of ($1M).


SenzaGen P&L

In the most recent fiscal year, SenzaGen reported revenue of $6M and EBITDA of ($901K).

SenzaGen is unprofitable as of last fiscal year, with gross margin of 65%, EBITDA margin of (14%), and net margin of (20%).

See analyst estimates for SenzaGen
Last FY202320242025202620272028
Revenue$6M$5M$6M$6M
Gross Profit$4M$4M$4M$4M
Gross Margin65%70%67%65%
EBITDA($901K)($1M)($813K)($901K)
EBITDA Margin(14%)(21%)(13%)(14%)
EBIT Margin(19%)(30%)(18%)(19%)
Net Profit($1M)($2M)($2M)($1M)
Net Margin(20%)(44%)(31%)(20%)

Financial data powered by Morningstar, Inc.

SenzaGen Stock Performance

SenzaGen has current market cap of $19M, and enterprise value of $18M.

Market Cap Evolution


SenzaGen's stock price is $0.58.

SenzaGen share price increased by 0.3% in the last 30 days, and by 3.8% in the last year.

SenzaGen has an EPS (earnings per share) of $-0.04.

See more trading valuation data for SenzaGen
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$18M$19M0.5%0.3%-5.8%3.8%$-0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

SenzaGen Valuation Multiples

SenzaGen trades at 2.9x EV/Revenue multiple, and (20.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for SenzaGen

SenzaGen Financial Valuation Multiples

As of May 8, 2026, SenzaGen has market cap of $19M and EV of $18M.

SenzaGen has a P/E ratio of (15.2x).

Last FY202320242025202620272028
EV/Revenue2.9x3.4x2.9x2.9x
EV/EBITDA(20.1x)(16.2x)(22.3x)(20.1x)
EV/EBIT(15.2x)(11.2x)(15.8x)(15.2x)
EV/Gross Profit4.5x4.8x4.3x4.5x
P/E(15.2x)(7.9x)(9.8x)(15.2x)
EV/FCF(13.6x)(8.3x)(12.1x)(13.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified SenzaGen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

SenzaGen Margins & Growth Rates

In the most recent fiscal year, SenzaGen reported gross margin of 65%, EBITDA margin of (14%), and net margin of (20%).

See estimated margins and future growth rates for SenzaGen

SenzaGen Margins

Last FY20242025202720282029
Gross Margin65%67%65%
EBITDA Margin(14%)(13%)(14%)
EBIT Margin(19%)(18%)(19%)
Net Margin(20%)(31%)(20%)
FCF Margin(21%)(24%)(21%)

SenzaGen Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth16%0%
Gross Profit Growth10%(3%)
EBITDA Growth(27%)11%
EBIT Growth(29%)4%
Net Profit Growth(19%)(35%)
FCF Growth(32%)(11%)

Data powered by FactSet, Inc. and Morningstar, Inc.

SenzaGen Operational KPIs

SenzaGen's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for SenzaGen
Last FY202320242025202620272028
Revenue per Employee$0.2M
Opex per Employee$0.2M
S&M Expenses to Revenue19%54%45%19%
G&A Expenses to Revenue15%38%32%15%
R&D Expenses to Revenue6%8%12%6%
Opex to Revenue84%100%85%84%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

SenzaGen Competitors

SenzaGen competitors include CurveBeam AI, EBM Technologies, Diagnos, Biosynex, NanoRepro, Predilife, Biomaxima, Immunovia, Synthetic MR and ContextVision.

Most SenzaGen public comparables operate across Medical Imaging & Diagnostics and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
CurveBeam AI3.3x3.6x(4.0x)(4.0x)
EBM Technologies2.3x20.0x
Diagnos215.3x(6.3x)
Biosynex0.7x(3465.7x)
NanoRepro2.6x0.7x(3.5x)(9.6x)
Predilife26.1x(4.1x)
Biomaxima1.2x13.7x
Immunovia66.1x23.6x(0.6x)(0.5x)

This data is available for Pro users. Sign up to see all SenzaGen competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About SenzaGen

When was SenzaGen founded?SenzaGen was founded in 2010.
Where is SenzaGen headquartered?SenzaGen is headquartered in Sweden.
How many employees does SenzaGen have?As of today, SenzaGen has over 34 employees.
Is SenzaGen publicly listed?Yes, SenzaGen is a public company listed on Nasdaq Stockholm.
What is the stock symbol of SenzaGen?SenzaGen trades under SENZA ticker.
When did SenzaGen go public?SenzaGen went public in 2017.
Who are competitors of SenzaGen?SenzaGen main competitors include CurveBeam AI, EBM Technologies, Diagnos, Biosynex, NanoRepro, Predilife, Biomaxima, Immunovia, Synthetic MR, ContextVision.
What is the current market cap of SenzaGen?SenzaGen's current market cap is $19M.
What is the current revenue of SenzaGen?SenzaGen's last fiscal year revenue is $6M.
What is the current EV/Revenue multiple of SenzaGen?Current revenue multiple of SenzaGen is 2.9x.
Is SenzaGen profitable?No, SenzaGen is not profitable.
How many companies SenzaGen has acquired to date?SenzaGen hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies SenzaGen has invested to date?SenzaGen hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to SenzaGen

Lists including SenzaGen

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial